PIVOT , Xavier

Last name: PIVOT

First name: Xavier

March 16, 2010 (v1)

Journal article

Metadata-only

Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy.

Bidard, François-Clément Mathiot, Claire Degeorges, Armelle

BACKGROUND: We investigated whether circulating tumor cells (CTCs) and circulating endothelial cells (CECs) predict clinical outcome of first-line chemotherapy combined with bevacizumab in metastatic breast cancer patients. PATIENTS AND METHODS: In a French substudy of the MO19391 trial, CTC and CEC counts (CellSearch system) at baseline and...

Uploaded on: December 3, 2022
May 2010 (v1)

Journal article

Metadata-only

Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer.

Barrios, Carlos Liu, Mei-Ching Lee, Soo Chin

This multicenter, randomized, open-label phase III trial (planned enrollment: 700 patients) was conducted to test the hypothesis that single-agent sunitinib improves progression-free survival (PFS) compared with capecitabine as treatment for advanced breast cancer (ABC). Patients with HER2-negative ABC that recurred after anthracycline and...

Uploaded on: December 3, 2022
May 31, 2013 (v1)

Conference paper

Metadata-only

A French prospective pilot study for identifying dihydropyrimidine dehydrogenase (DPD) deficiency in breast cancer patients (pts) receiving capecitabine (cap)

Etienne-Grimaldi, Marie-Christine Ferrero, Jean-Marc Thomas, Fabienne

Background: For fluoropyrimidines, and especially cap, Health Authorities point out that DPD deficiency confers a significant risk of major toxicity (tox). Identification of at-risk pts is thus relevant. This multicentric prospective study of the French GPCO group (Groupe de Pharmacologie Clinique Oncologique, Unicancer) evaluated the...

Uploaded on: December 2, 2022

PIVOT , Xavier

Recent uploads